Dr. Armstrong on Precision Medicine for Metastatic Prostate Cancer

Andrew J. Armstrong, MD
Published: Monday, Sep 25, 2017



Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses precision medicine for patients with metastatic prostate cancer.

Most of the approved drugs for patients with metastatic prostate cancer include immunotherapy, hormonal therapy, and chemotherapy. Precision medicine is the ability to use biomarkers for the optimal therapy, which makes treatment decisions easier for these patients, states Armstrong.

A blood test called the AR-V7 assay can help determine which patients will become resistant to enzalutamide (Xtandi) or abiraterone acetate (Zytiga), explains Armstrong.
 


Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses precision medicine for patients with metastatic prostate cancer.

Most of the approved drugs for patients with metastatic prostate cancer include immunotherapy, hormonal therapy, and chemotherapy. Precision medicine is the ability to use biomarkers for the optimal therapy, which makes treatment decisions easier for these patients, states Armstrong.

A blood test called the AR-V7 assay can help determine which patients will become resistant to enzalutamide (Xtandi) or abiraterone acetate (Zytiga), explains Armstrong.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x